<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33058338</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov Disord</ISOAbbreviation></Journal><ArticleTitle>A Novel Duplication in ATXN2 as Modifier for Spinocerebellar Ataxia 3 (SCA3) and C9ORF72-ALS.</ArticleTitle><Pagination><StartPage>508</StartPage><EndPage>514</EndPage><MedlinePgn>508-514</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.28334</ELocationID><Abstract><AbstractText Label="BACKGROUND">The ataxin-2 (ATXN2) gene contains a cytosine-adenine-guanine repeat sequence ranging from 13 to 31 repeats, but when surpassing certain thresholds causes neurodegeneration. Genetic alterations in ATXN2 other than pathological cytosine adenine guanine (CAG) repeats are unknown.</AbstractText><AbstractText Label="METHODS/RESULTS">We have identified a 9-base pair duplication in the 2-gene ATXN2 sense/antisense region. The duplication was found in a Swedish family with spinocerebellar ataxia 3 with parkinsonism, conferring a deviated age at onset unexplained by the concomitant presence of ATXN2 intermediate alleles. Similarly, C9ORF72 amyotrophic lateral sclerosis cases bearing the same duplication had earlier age at onset than those with C9ORF72 and ATXN2 intermediate alleles. No effect was evident in Parkinson's disease (PD) cases without known PD gene mutations.</AbstractText><AbstractText Label="CONCLUSIONS">We describe the first genetic alteration other than the known intermediate-range CAG repeats in ATXN2. This 9-base pair duplication may act as an additional hit among carriers of pathological nucleotide expansions in ATXN3 and C9ORF72 with ATXN2 intermediate. &#xa9; 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laffita-Mesa</LastName><ForeName>Jose Miguel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (CNS), Neuro Svenningsson, J5:20 Bioclinicum, Karolinska Universitetssjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nennesmo</LastName><ForeName>Inger</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (CNS), Neuro Svenningsson, J5:20 Bioclinicum, Karolinska Universitetssjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Paucar</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (CNS), Neuro Svenningsson, J5:20 Bioclinicum, Karolinska Universitetssjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Svenningsson</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (CNS), Neuro Svenningsson, J5:20 Bioclinicum, Karolinska Universitetssjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593752">ATXN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C565957">Amyotrophic Lateral Sclerosis 2, Juvenile</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017827" MajorTopicYN="Y">Machado-Joseph Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATXN2</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">SCA3</Keyword><Keyword MajorTopicYN="N">gene modifier</Keyword><Keyword MajorTopicYN="N">genotype-phenotype correlations</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>15</Day><Hour>17</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33058338</ArticleId><ArticleId IdType="pmc">PMC7983901</ArticleId><ArticleId IdType="doi">10.1002/mds.28334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996;14(3):269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G, Saudou F, Yvert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996;14(3):285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanpei K, Takano H, Igarashi S, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 1996;14(3):277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffita&#x2010;Mesa JM, Vel&#xe1;zquez&#x2010;P&#xe9;rez LC, Santos Falc&#xf3;n N, et al. Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles. Eur J Hum Genet 2012;20(1):41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234519</ArticleId><ArticleId IdType="pubmed">21934711</ArticleId></ArticleIdList></Reference><Reference><Citation>De mattos EP, Leotti VB, Soong BW, et al. Age at onset prediction in spinocerebellar ataxia type 3 changes according to population of origin. Eur J Neurol 2019;26(1):113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">30125433</ArticleId></ArticleIdList></Reference><Reference><Citation>Tezenas du montcel S, Durr A, Bauer P, et al. Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain 2014;137(9):2444&#x2013;2455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132646</ArticleId><ArticleId IdType="pubmed">24972706</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Z, Chen Z, Wang C, et al. Two novel SNPs in ATXN3 3&#x2019; UTR may decrease age at onset of SCA3/MJD in Chinese patients. PLoS One 2015;10(2):e0117488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331546</ArticleId><ArticleId IdType="pubmed">25689313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettencourt C, Raposo M, Kazachkova N, et al. The APOE &#x3b5;2 allele increases the risk of earlier age at onset in Machado&#x2010;Joseph disease. Arch Neurol 2011;68(12):1580&#x2013;1583.</Citation><ArticleIdList><ArticleId IdType="pubmed">22159055</ArticleId></ArticleIdList></Reference><Reference><Citation>Li PP, Sun X, Xia G, et al. ATXN2&#x2010;AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis. Ann Neurol 2016;80(4):600&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6555153</ArticleId><ArticleId IdType="pubmed">27531668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Xu Y, Feng X, et al. Linkage analysis and whole&#x2010;exome sequencing exclude extra mutations responsible for the Parkinsonian phenotype of spinocerebellar ataxia&#x2010;2. Neurobiol Aging 2015;36(1):545.e1&#x2013;e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25189117</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino E, Mancini C, Boschi S, et al. ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. Neurobiol Aging 2019;73:231.e7&#x2013;231.e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30342763</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C, Anquetil V, Camuzat A, et al. Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. Acta Neuropathol Commun 2018;6(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977499</ArticleId><ArticleId IdType="pubmed">29848387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tojima M, Murakami G, Hikawa R, et al. Homozygous 31 trinucleotide repeats in the SCA2 allele are pathogenic for cerebellar ataxia. Neurol Genet 2018;4(6):e283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6244019</ArticleId><ArticleId IdType="pubmed">30533529</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf3;brega C, Carmo&#x2010;silva S, Albuquerque D, et al. Re&#x2010;establishing ataxin&#x2010;2 downregulates translation of mutant ataxin&#x2010;3 and alleviates Machado&#x2010;Joseph disease. Brain 2015;138(Pt 12):3537&#x2013;3554.</Citation><ArticleIdList><ArticleId IdType="pubmed">26490332</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Sellier C, Campanari ML, Charlet&#x2010;berguerand N, Kabashi E. The most prevalent genetic cause of ALS&#x2010;FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway. Autophagy 2016;12(8):1406&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968221</ArticleId><ArticleId IdType="pubmed">27245636</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchihara T, Fujigasaki H, Koyano S, Nakamura A, Yagishita S, Iwabuchi K. Non&#x2010;expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias&#x2010;triple&#x2010;labeling immunofluorescence study. Acta Neuropathol 2001;102(2):149&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">11563629</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, Campanari M&#x2010;L, Corbier CJ, et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin&#x2010;2 to induce motor neuron dysfunction and cell death. EMBO J 2016;35(12):1276&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Blitterswijk M, Mullen B, Heckman MG, et al. Ataxin&#x2010;2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging 2014;35(10):2421.e13&#x2013;e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105839</ArticleId><ArticleId IdType="pubmed">24866401</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh DP, Nguyen DT, Pulst&#x2010;korenberg JB, Brice A, Pulst SM. Parkin is an E3 ubiquitin&#x2010;ligase for normal and mutant ataxin&#x2010;2 and prevents ataxin&#x2010;2&#x2010;induced cell death. Exp Neurol 2007;203(2):531&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788988</ArticleId><ArticleId IdType="pubmed">17097639</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen NE, Drost J, Gispert S, et al. Search for SCA2 blood RNA biomarkers highlights Ataxin&#x2010;2 as strong modifier of the mitochondrial factor PINK1 levels. Neurobiol Dis 2016;96:115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">27597528</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, et al. Ataxin&#x2010;2 intermediate&#x2010;length polyglutamine expansions are associated with increased risk for ALS. Nature 2010;466(7310):1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Li YR, Chesi A, et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 2011;76(24):2062&#x2013;2065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111240</ArticleId><ArticleId IdType="pubmed">21562248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>